A Randomized Phase 2 Trial of Nivolumab, Relatlimab plus Ipilimumab vs. Nivolumab plus Ipilimumab in first-line advanced renal cell carcinoma (RCC)
Clinical Trial Grant
Awarded By
The University of Texas MD Anderson Cancer Center
Start Date
September 15, 2025
End Date
September 21, 2030
Awarded By
The University of Texas MD Anderson Cancer Center
Start Date
September 15, 2025
End Date
September 21, 2030